Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study
Thyroid® · 2023-03 · 33 (3) · 312-320
DOI: 10.1089/thy.2022.0542 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Thyroid®, online erschienen am 16.03.2023. Verfasst von Leonardo Barbi Walter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thyroid Unit, Hospital de Clínicas de Porto Alegre, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Papillary, Thyroid Neoplasms, Carcinoma. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
The most frequent site of recurrence of differentiated thyroid cancer (DTC) is cervical lymph nodes (LNs), which often necessitates repeated surgical interventions and morbidity in a generally indolent disease. Data on active surveillance (AS) of small cervical nodal metastasis are still scarce, particularly in real-world clinical settings. In this study, we evaluated the DTC outcomes of AS of metastatic cervical LNs and explored factors associated with disease progression.
Methods
We conducted a retrospective cohort study, including DTC patients with biopsy-proven metastatic cervical LNs, who were followed on AS in a tertiary care, university-based institution in Brazil. The inclusion criteria were cervical metastasis ≤2.0 cm and an AS duration of at least 6 months. We excluded lesions with aggressive histology, those in close proximity to or invading local structures. The primary outcome was disease progression (enlargement ≥3 mm in any diameter or a new cervical metastasis).
Results
Data from 40 patients were analyzed. Most were female (77.5%) and had papillary thyroid cancer (97.5%). The mean age was 47.0 (± standard deviation 15.8) years. The 8th edition of the tumor, node, metastasis stage (TNM8) staging for DTC was as follows: 29 in stage I (74.4%), 8 in stage II (20.5%), and 2 in stage IV (5.0%). The median maximum LN diameter was 0.9 (interquartile range [IQR], 0.8–1.3) cm, and the median AS follow-up duration was 27.5 (IQR, 16.5–47.3) months. Disease progression occurred in 14 (35%) patients: 7 (17.5%) due to enlargement ≥3 mm, and 7 (17.5%) had new cervical metastasis. The cervical progression-free survival was 51.0 (confidence interval, 47.0–55.0) months. No demographic, oncological, or biochemical factors were associated with disease progression. Of the 14 patients with disease progression, 8 were referred for surgery. No permanent surgical complications were reported. Of the six patients who remained on AS despite disease progression, five showed no further progression during subsequent follow-up (range 6–40 months).
Conclusions
We observed that most small metastatic cervical LNs remained stable and were safely managed with AS. Nevertheless, these observations are limited by the retrospective design, small sample size, and short follow-up. Further prospective and long-term studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Thyroid Unit, Hospital de Clínicas de Porto Alegre, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Department of Pharmacology, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Department of Radiology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
- Department of Pathology, Hospital de Clínicas de Porto Alegre, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
ORCID-Profile: Leonardo Barbi Walter
Zitieren
APA
Walter, L. B., Scheffel, R. S., Zanella, A. B., Farenzena, M., Faccin, C. S., Graudenz, M. S., Dora, J. M., & Maia, A. L. (2023). Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study. Thyroid®, 33(3), 312-320. https://doi.org/10.1089/thy.2022.0542
Vancouver
Walter LB, Scheffel RS, Zanella AB, Farenzena M, Faccin CS, Graudenz MS, et al. Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study. Thyroid®. 2023;33(3):312-320. doi:10.1089/thy.2022.0542
BibTeX
@article{Walter2023,
author = {Walter, Leonardo Barbi and Scheffel, Rafael Selbach and Zanella, Andre Borsatto and Farenzena, Mauricio and Faccin, Carlo Sasso and Graudenz, Marcia Silveira and Dora, José Miguel and Maia, Ana Luiza},
title = {Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study},
journal = {Thyroid®},
year = {2023},
volume = {33},
number = {3},
pages = {312--320},
doi = {10.1089/thy.2022.0542}
}
EUVIMED